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Abstract
Insertional mutagens such as viruses and transposons are a useful tool for performing forward
genetic screens in mice to discover cancer genes. These screens are most effective when
performed using hundreds of mice, however until recently a major limitation to performing
screens on this scale has been the cost effective isolation and sequencing of insertion sites. Here
we present a method for the high-throughput isolation of insertion sites using a highly efficient
splinkerette-PCR method coupled with capillary or 454 sequencing. This protocol includes a
description of the procedure for DNA isolation, DNA digestion, linker or splinkerette ligation,
primary and secondary PCR amplification, and sequencing. This method, which takes about 1
week to perform, has allowed us to isolate hundreds of thousands of insertion sites from mouse
tumours and, unlike other methods, has been specifically optimised for the isolation of insertion
sites generated with the murine leukaemia virus (MuLV), and can easily be performed in 96 well
plate format for the efficient multiplex isolation of insertion sites.
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INTRODUCTION
Insertional mutagenesis in mice
Human tumours arise as a result of the sequential acquisition of mutations, which may
include point mutations, changes in DNA copy number, translocations and epigenetic
changes in the genome. Not all of these alterations are causally implicated in oncogenesis,
and separating the ‘driver’ mutations from the ‘passenger’ mutations1 is not possible without
functional validation in vitro or preferably in vivo. Insertional mutagenesis in the mouse
using either viruses or transposons makes it possible to perform genome-wide screens for
genes that co-operate in cancer formation. Once integrated in the genome the provirus or
transposon acts as a ‘tag’ allowing its location to be determined and effects on gene function
assessed. Therefore insertional mutagenesis studies in the mouse are a useful complement to
the analysis of human cancer genomes and facilitate the identification of ‘driver’ cancer
genes.
Historically, insertional mutagenesis screens in mice have been performed using slow
transforming retroviruses. These viruses include murine leukaemia viruses (MuLV) and
mouse mammary transforming viruses (MMTV), which generate tumours of the lymphoid
system and mammary gland, respectively2. More recently transposon based methods, such
as those that use the Sleeping Beauty transposon3, have been developed to allow
mutagenesis to be performed in other tissues including the liver4, brain5 and soft tissue
compartments6. Although conceptually straightforward, isolating and sequencing insertion
sites (either viral or transposon-mediated) from hundreds or thousands of tumours can be
cumbersome and expensive. Hence, methods that allow insertion sites to be efficiently
amplified and sequenced are critical for the success of these screens.
Strategies for isolating insertion sites
To isolate insertion sites it was once necessary to generate genomic libraries of each tumour
and to screen these by colony lift for genomic fragments containing a virus-genome
junction, usually using viral long terminal repeat (LTR) sequences as probes7. More recently
a variety of approaches have been developed for insertion site isolation including inverse-
PCR8, vectorette9 or splinkerette-PCR10, panhandle-PCR, Alu-PCR, capture-PCR and
boomerang DNA amplification11. Although inverse-PCR has been a widely used approach
for isolating insertion sites, it is relatively inefficient compared to other PCR-based
approaches11. Approaches such as panhandle-PCR, Alu-PCR, capture-PCR and boomerang
DNA amplification have not been widely employed because they can be problematic to
optimise and do not readily lend themselves to scaling-up for high-throughput applications.
Vectorette-PCR can be highly sensitive but is prone to the amplification of contaminants by
‘end-repair priming’9. End-repair priming involves the free cohesive ends of unligated
vectorettes and inserts which are based on restriction sites that produce 5′ overhangs.
During the first cycle of PCR these ends are ‘filled in’ and after the subsequent denaturing
step, these ends are able to anneal to each other and to initiate priming. Extension across a
vectorette sequence at either end of the insert molecule will result in the production of a
sequence complementary to the vectorette primer. When this happens exponential PCR
amplification may occur without involvement of the specific target DNA primer and the
pool of PCR products in the reaction will become swamped by this contaminant, which is
usually preferentially amplified. In contrast splinkerette-PCR10,12, which is a variant of
ligation-mediated PCR, was developed to overcome the problem of ‘end-repair priming’ by
using a splinkerette ‘hairpin loop’ (Fig. 1a,b). Although not perfect, because like any PCR-
based method Splinkerette-PCR is potentially prone to PCR amplification bias and
contamination, it has become the most widely accepted technique for the amplification of
viral and transposon insertion sites.
The principle of splinkerette-PCR
Splinkerette-PCR was originally developed to enable PCR amplification of sequences that
lie between a known DNA sequence10, such as a viral LTR or transposon IR/DR, and a
nearby restriction site. Unlike vectorettes, which contain a central DNA mismatch within
them, splinkerette adaptors incorporate a hairpin structure (Fig. 1b). Annealing of oligos to
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create the splinkerette adaptor creates an overhang compatible with overhangs generated by
the restriction of the (genomic) DNA with the restriction enzyme of choice. However, since
the oligonucleotides used to create the splinkerette adaptor are not phosphorylated at their 5′
terminus they should only undergo single stranded ligation to the 5′ end of the template
sequences. To amplify DNA a primer that can only bind to the newly synthesized strand of
the splinkerette adaptor is used in the PCR reaction. This ensures that DNA cannot be
amplified until synthesis from a primer that binds to the target sequence, for example the
viral LTR, has been achieved. This feature improves specific amplification of splinkerette-
adapted sequences. Furthermore, during the elongation step of the PCR reaction the free 3′
end of the splinkerette will ‘flip back’ on itself to form a stable double stranded DNA
hairpin which is unable to participate in end-repair priming. An additional factor that
increases the specificity of the splinkerette reaction is that only one-strand is available for
non-specific priming, unlike vectorettes where mis-priming can occur from both strands.
Some splinkerette protocols have also been adapted to incorporate a C3 spacer ‘blocking
group’ at the 3′ end of the splinkerette oligos which can also help to prevent mis-
priming6,10. Collectively, these features make splinkerette-PCR efficient, accurate and
highly sensitive.
Sequence analysis of splinkerette insertion sites
Tumours generated using either transposons or retroviruses are mostly oligoclonal. In
addition, cells within each tumour contain multiple insertion events making the
amplification of insertion sites from a tumour a multiplex reaction. For sequence analysis it
is necessary to de-multiplex each splinkerette-PCR so that the sequence of individual
insertion sites can be retrieved.
There are several approaches that can be used for de-multiplexing. The first is shotgun
cloning of individual splinkerette-PCR products followed by capillary read sequencing, and
the second is barcode splinkerette-PCR followed by 454 parallel sequencing. The major
advantage of shotgun cloning followed by capillary read sequencing is that it is extremely
robust. We have developed an approach called TOPO-shotgun (Fig. 2) which we have used
to generate the DNA sequence of over 100,000 insertion sites from over 1,000 splinkerette-
PCR reactions generated from both retroviral13 and transposon induced tumours. The other
advantage of TOPO-shotgun is that the sequences generated from capillary reads are long,
up to 1 Kb, so it is possible to obtain the sequence from the viral LTR or transposon IR/DR,
the sequence of the junction between the insertional mutagen and the genome, a length of
genomic sequence, and to also read sequence into the splinkerette adaptor. This facilitates
the removal of contaminated splinkerette-PCR products and the accurate alignment and
orientation of insertion sites on the genome. The major disadvantage of TOPO-shotgun
cloning is that it is expensive and requires considerable infrastructure for colony picking,
prepping and sequencing. It is however still the method of choice for the analysis of small
numbers of tumour samples (<20) where the use of parallel sequencing is unnecessary and
uneconomical.
The alternative approach for obtaining the sequence of insertion sites is to employ 454
parallel sequencing of pools of barcoded splinkerette-PCR reactions from multiple
independent tumours (Fig. 2). Because 454 employs single molecule sequencing technology,
pools of PCR products can be effectively de-multiplexed on the machine. By incorporating
‘barcode’ sequences (short DNA sequence identifiers) in the splinkerette-PCR primers, it is
possible to pool together splinkerette products from multiple tumours and to use the barcode
as a tag to determine which sequence belongs to each tumour within the pool. 454
sequencing is a very efficient way of analyzing insertion sites. A single 454 run can be
performed in one day, yielding over 400 Mb of sequence14. Importantly, it is possible to run
up to eight independent samples, or pools of samples, on each flow cell. DNA sequence
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reads on the Roche 454 Gs20 machine are short, ~100 bp whereas the sequences generated
by the 454 FLX are on average 250 bp in length. For most insertion sites the length of DNA
sequence generated on the FLX is sufficient to identify the IR/DR or LTR, the junction
between the IR/DR or LTR and the genome and in many cases to generate sequence into the
splinkerette adaptor. Although this is the first working protocol describing the use of
splinkerette-PCR and 454 for insertion site isolation from MuLV induced tumours13 similar
methods exist for HIV and other viruses15.
EXPERIMENTAL DESIGN
In this protocol we have focused on the isolation of insertion sites from MuLV-induced
mouse lymphomas but with adaptation of the primer sequences this protocol is applicable to
the isolation of insertion sites generated by any insertional mutagen. Here we present an
optimised protocol for the amplification of splinkerette-PCR products representing the
junction between the MuLV viral U3LTR and a genomic insertion point. This protocol uses
the restriction enzyme Sau3AI, and a compatible splinkerette adaptor, but can be adapted for
any restriction enzyme and splinkerette adaptor combination. The technique we describe is
applicable to the isolation of insertion sites from transposons or other insertional mutagens
with adaptation of the oligonucleotides used at each PCR step and the restriction enzymes
used for cutting the genomic DNA. For simplicity this protocol is in single tube format but
can be scaled up to 96-well plate format. We have provided information on the equipment
and reagents needed for performing this splinkerette method in 96-well plates throughout
this protocol.
DNA extraction method
The quality of DNA used for splinkerette-PCR is critical. The DNA must be free of salt or
other contaminants that may affect the PCR amplification reactions. We have obtained good
results using DNA extracted with Gentra Puregene kits (Qiagen). Although it is possible to
perform splinkerette-PCR using DNA extracted by other methods, such as phenol-
chloroform, we have found this less successful.
Choice of restriction enzyme
Since splinkerette-PCR is a multiplex-PCR reaction it will generally favour the
amplification of shorter PCR products from within the pool of insertion sites found within a
sample. The sequence of the genomic DNA between the viral LTR or transposon IR/DR is
also likely to influence the recovery of an insertion since GC rich sequences may be harder
to amplify. To obtain maximal coverage of insertion sites it is preferable to use multiple
restriction enzymes on each tumour DNA and several independent splinkerette reactions.
For the isolation of retroviral insertion sites (from MuLV-induced tumours), we have had
success using Sau3AI, Tsp509I, and MspI although best results have been obtained with
Sau3AI and MspI. For isolation of transposon insertion sites (from Sleeping Beauty-induced
tumours), we have used NlaIII and BfaI6. These enzymes all have a 4 bp recognition
sequence and the average distance between each restriction site in the mouse genome is 414
bp (SD 8,014 bp) for Sau3AI, 170 bp (SD 5,142 bp) for Tsp509I, 1,665 bp (SD16,258 bp)
for MspI, 213 bp (SD 5,748 bp) for NlaIII and 316 bp (SD 340 bp) for BfaI. It is unlikely
that saturation isolation of insertion sites is possible by using splinkerette-PCR, or any other
PCR based method. However, it is clear that the absolute recovery of insertion sites
increases when additional enzymes are used to analyse each tumour in separate splinkerette-
PCR reactions.
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Design of the splinkerette adaptor sequences
Although several splinkerette adaptor sequences have been developed the protocols
described below use an adaptor sequence first reported by Mikkers et al16.
Digestion of the adaptor-ligated splinkerette products
When the primary amplification primers are in a sequence that is repeated internally (for
example the U3 LTR of MuLV) an appropriate restriction site must be found for digestion of
the ligated DNA to prevent amplification of internal fragments. This site must be closer to
the internal primer than the enzyme used to ligate the splinkerette to the DNA, i.e. digestion
of the genomic DNA. In the case of isolating insertion sites from MuLV-induced tumour
genomic DNA, it is necessary to digest the adaptor-ligated splinkerette genomic DNA to
prevent amplification of internal MuLV fragments from the internal U3 LTR sequence
during the primary amplification PCR step. If Sau3AI, Tsp509I or MspI are used, then
EcoRV is recommended for digestion of the adaptor-ligated splinkerette products since the
EcoRV site is closer to the internal LTR than these sites (Fig. 1a).
Experimental Controls
As with any PCR-based protocol it is important to always run a ‘water only’ negative
control at each PCR step to ensure that there is no systematic contamination of reagents. We
also recommend including control of DNA that does not contain insertion sites. The reason
for this control is to ensure that non-specific amplification of sequence from endogenous
‘psuedo-LTR’ sequencing does not occur. An optimal result from splinkerette-PCR is a
ladder of bands, as shown in Fig. 1c. Novice users of this protocol may wish to run a
positive control that produces a known banding pattern on the agarose gel has described in
the expected results.
MATERIALS
Reagents
! CAUTION - When handling all the reagents wear gloves and suitable protective clothing,
avoid contact with skin and eyes and do not eat, drink or smoke. For further information for
individual products, search at http://www.sigmaaldrich.com/technical-service-home/
product-catalog.html.
Gentra Purgene Cell Kit [Qiagen, 158767]
! CAUTION - Some of the reagents used in this kit are classed as irritants. Gloves, lab coats,
and protective eyewear should worn when using this kit.
Propan-2-ol (NORMAPUR AR analytical reagent, iso-propyl alcohol) [VWR, 20842.323]
! CAUTION - Propan-2-ol is flammable and is an irritant. Always store in an appropriate
flammables cabinet and handle away from spark sources or flames. Gloves, lab coats, and
protective eyewear should be worn when handling Propan-2-ol.
Ethanol (99.7% v/v, AnalaR) [VWR, 101077Y]
Sau3A1 (4 U μl−1; supplied with 10× buffer & 100× BSA) [NEB, R0169]
HPLC-purified oligonucleotides (Table 1) [Sigma-Genosys]
EcoRV (20 U μl−1; supplied with 10× buffer & 100× BSA) [NEB, R0195S]
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NEB buffer 2 [NEB, B7002S]
Bacto-tryptone [Difco, 0123-01-1]
Bacto-yeast extract [Difco, 0127-05-3]
Sodium Chloride, NaCl [Sigma, S9625]
Potassium Chloride, KCl [Sigma, P3911]
Glucose [Sigma, G8270]
Sodium Hydroxide, NaOH [Sigma, S8045]
! CAUTION - NaOH is an irritant. Gloves, lab coats, and protective eyewear should worn
when handling NaOH or solutions containing it.
Bacto-agar [Difco, 214530]
Ampicillin [Sigma, A6140]
T4 DNA ligase (20 U μl−1; supplied with 10× buffer) [NEB, M0202S]
QIAquick Gel Extraction Kit [Qiagen, 28704]
! CAUTION - Some of the reagents used in this kit are classed as irritants. Gloves, lab coats,
and protective eyewear should worn when using this kit.
SigmaSpin™ Sequencing Reaction Clean-Up [Sigma, S4309]
CRITICAL Required if splinkerette-PCR is to be performed in 96-well plates.
dNTP Set (100 mM Solution, 25 μMol) [Abgene, AB-0315/A]
Pfu Turbo Hotstart DNA Polymerase (supplied with buffer) [Stratagene, 600320]
Qiagen Multiplex PCR kit [Qiagen, 206143]
1 Kb DNA Ladder [Invitrogen, 15615024]
Agarose (electrophoresis grade) [Invitrogen, 15510027]
Ethidium Bromide Solution (10 mg/mL) [Sigma-Aldrich, E1510]
! CAUTION - Ethidium Bromide is a suspected mutagen and is a possible carcinogen.
Gloves, lab coats, and protective eyewear should worn when handling this reagent and any
gels or solutions carrying it. Ethidium Bromide containing material should be disposed of in
accordance with local institutional safety procedures.
TOPO TA Cloning® Kit for Sequencing (containing pCR®4-TOPO®) [Invitrogen,
K4575-40]
ElectroMAX DH10B™ Cells [Invitrogen, 18290-015]
†GS emPCR kit III (Amplicon B, paired end) [Roche, 04891392001]
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CRITICAL Required if splinkerette-PCR sequencing is to be performed on the 454
platform.
†Exonuclease 1 (20,000 U/mL) [M0293L]
CRITICAL Required if splinkerette-PCR sequencing is to be performed on the 454
platform.
†Shrimp alkaline phosphatase (2,000 U/mL). Supplied with 10×SAP buffer [M0289B]
CRITICAL Required if splinkerette-PCR sequencing is to be performed on the 454
platform.
Equipment
1.5 mL microtubes [Axygen, 311-04-051]
PCR tubes and lids (strips of 8) [Abgene, AB-0771 and -0784]
Thin-walled 96-well PCR plates [Abgene, SP-1043]
CRITICAL These are required if splinkerette-PCR is to be performed in 96-well plates.
Electroporation Cuvettes (0.1 cm, Brown Top) [Biorad, 1652089]
Deep-well 96-well plates [PLPL0082]
Millipore filter plates [LSKMPCR50]
CRITICAL Required if splinkerette-PCR sequencing is to be performed on the 454
platform. 96 well plate thermal cycler
37°C incubator
Heating block
Gel running equipment including gel tank and power supply.
Micro-centrifuge
Electroporator
Benchtop 96 well plate centrifuge
CRITICAL Necessary if splinkerette-PCR is to be performed in 96 well plates.
454 FLX DNA sequencer
CRITICAL If 454 FLX instruments are not available, commercial access to 454 technology
can be obtained through the following pay for service organizations including:
www.454.com
http://www.mwg-biotech.com
http://www.cogenics.com
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www.gatc-biotech.com
http://www.biotech.ufl.edu/services.html
www.macrogen.com/
Reagent Set-up
Preparation of the splinkerette adapter mix—‘Long strand adapter’ and ‘short strand
adapter’ oligonucleotides (shown in Table 1) need to be HPLC-purified. The oligos should
be resuspended in 5× NEB buffer 2 (250 mM NaCl, 50 mM Tris-HCl, 50 mM MgCl2, 1 mM
Dithiothreitol; pH 7.9) to a concentration of 50 μM. Stocks can be frozen at −20°C. Add 50
μL of 50 μM long strand adapter and 50 μL of 50 μM short strand adapter to a 1.5 mL tube
and vortex to mix. Each adapter primer will be present at a final concentration of 25 μM.
This adapter mix can be stored indefinitely at −20°C and will provide enough splinkerette-
adaptor for 100 splinkerette-PCR reactions.
SOC medium—To 950 mL double-distilled water, add 20 g Bacto-tryptone, 5 g Bacto-
yeast extract, 0.5 g NaCl and 2.5 mL of 1 M KCl. Adjust the pH to 7.0 with 10 N NaOH and
then make up to final volume of 1 L using double-distilled water. Autoclave to sterilise, then
store at room temperature (21°C–25°C). Add 20 mL sterile 1 M glucose immediately before
use. SOC medium is stable for 1 week after the addition of the glucose. SOC medium with
glucose provides a very rich environment for bacterial growth and even with good sterile
technique can easily become contaminated. It is advisable to inspect SOC medium for
contamination, which will make the medium ‘cloudy’, prior to use.
LB+amp plates—Add 10 g Bacto-tryptone, 5 g Bacto-yeast extract, 10 g NaCl and 15 g
Bacto-agar to double-distilled water (final volume is 1 L). Autoclave to sterilize, cool to
55°C, add 1 mL 100 mg/mL ampicillin (amp), then pour into sterile 10 cm2 petri dishes.
Store at 4°C and dispose of unused plates after 3 weeks.
LB+amp medium—Add 10 g Bacto-tryptone, 5 g Bacto-yeast extract and 10 g NaCl to
double-distilled water (final volume is 1 L). Autoclave to sterilize, then store at room
temperature. To 1 L add 1 mL 100 mg/mL ampicillin. After the addition of ampicillin store
medium for a maximum of 2 weeks at 4°C.
PROCEDURE
Tumour Collection and Storage
1: Collect mouse tumour material into screw-topped cryo-vials and snap frozen in liquid
nitrogen. Tissue can be stored at −80°C (or in liquid nitrogen for long term storage).
Extraction of tumour genomic DNA – TIMING: 4 hr.
2: Remove cryo-vial from the liquid nitrogen and place on dry ice. With a sharp scalpel
blade shave 5-10 mg of tissue from the tumour sample and extract the genomic DNA using
the Gentra Purgene Cell Kit (Qiagen) according to the manufacturer’s instructions. Unused
tissue can be returned to the cryovial and stored in liquid nitrogen.
Caution – The solutions used with in the Gentra Puregene Cell Kit contain irritants such as
proteinase K and lyticase. Gloves, lab coats and eye protection are recommended. Liquid
nitrogen should be handled with care.
Pause Point – The DNA can be stored at 4°C or at −20°C indefinitely.
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Digestion of tumour genomic DNA with restriction enzyme – TIMING: 12-16 hr.
3: Digest the genomic DNA by setting up the reaction listed below in a 1.5 mL tube. DNA
quantities in the range of 0.5-5 μg are acceptable. 2 μg is optimal. We suggest quantifying
DNA by spectrophotometry using a nanodrop.
Component Amt. per tube (μL) Final
Genomic DNA 1* 2 μg genomic DNA
Sau3A1 Enzyme (20 U/μL) 2 40 U
10× NEB buffer 1 3 1×
Acetylated BSA (10 mg/mL) 1 0.33 μg/μL
Double distilled Water 23* -
Final volume 30
*Varies depending on DNA concentration.
4: Incubate the digestions at 37°C overnight (12-16 hr), either in a heating block or
incubator.
Pause Point – The digested genomic DNA can be stored at 4°C or at −20°C indefinitely.
Splinkerette-adaptor ligation– TIMING: 12 hr.
5: Thaw the adaptor mix (prepared as described in ‘reagent set up’) on ice. Pipette the
desired amount into a PCR tube (1 μL of adaptor mix per digested genomic DNA sample
from step 4). The adapter mix is then denatured and annealed by heating it to 95°C for 5 min
and then cooling to room temperature at the rate of 1°C every 15 sec. This is best performed
in a thermal cycler. Once completed the PCR tube should be kept on ice.
6: Immediately before use, heat the Sau3AI-digested genomic DNA to 65°C for 20 min then
place on ice. Set-up the following splinkerette adaptor ligation reaction:
Component Amt. per tube (μL) Final
Sau3AI digested genomic DNA (2 μg in 30 μL) 4.5 300 ng (~2 pmol)*
Adaptor mix (25 μM) 1 25 pmol (10-fold molar excess)
T4 DNA-ligase (20 U μl) 1 20 U
10× T4 DNA-ligase buffer 4 1×
Double distilled Water 29.5 -
Final volume 40
*Using a 4 bp restriction enzyme, 300 ng genomic DNA equates to ~1-2 pmol genomic DNA depending on the enzyme
used.
7: Incubate the ligation reaction at 4°C overnight (12-16 hr).
8: Heat inactivate the T4 DNA ligase at 65°C for 20 min (in a heating block).
Pause Point – The spinkerette ligation reaction can be stored at −20°C indefinitely.
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Digestion to remove genomic DNA fragments with splinkerette-adaptor ligated on both
ends. – TIMING: 6 hr.
9: EcoRV digestion of the ligation reaction (from step 8) removes any adaptor that has
ligated onto the LTR-end of the Sau3AI digested genomic DNA (Fig. 1a) and prevents
amplication of internal proviral fragments. Set-up the following digestion reaction in a 1.5
mL tube:
Component Amt. per tube (μL) Final
Splinkerette adaptor ligation 40 -
10× NEB buffer 3 10 1×
EcoRV(20 U/μL) 1 20 U
Acetylated BSA (10 mg/mL) 1 0.1 μg/μL
Double distilled Water 48 -
Final volume 100
10: Incubate the tube at 37°C for at least 6 hr (overnight is permitted).
11: Heat inactivate the enzyme by heating the tube at 65°C for 20 min (in a heating block).
Pause Point – The EcoRV-digested spinkerette ligation reaction can be stored at −20°C
indefinitely.
Clean up the EcoRV digestion reaction – TIMING: 10 mins.
12: To clean up the splinkerette adaptor ligated DNA use the QIAquick Gel Extraction Kit
according to the manufacturer’s instructions, with the exception that the DNA does not need
to be run on an agarose gel. Simply add 600 μL of Buffer QG (supplied in the kit) to the
reaction from step 11 and complete the protocol as per the manufacturer’s instructions. Elute
the DNA in 40 μL of 10 mM Tris (pH 7.4).
Caution – Some of the solutions used with the QIAquick Gel Extraction Kit contain
chaotropic salts which are irritants. Gloves, lab coats and eye protection are recommended.
13: Although not always necessary, the samples can be quantified using a nanodrop (and are
typically 5-15 ng/μL).
Pause Point – The purified spinkerette ligation reaction can be stored at −20°C indefinitely.
Primary PCR Amplification – TIMING: 2 hr.
14: To amplify the junction between the genome and the viral insertion a nested-PCR
reaction is used. Set-up the primary PCR as follows using the proofreading enzyme, Pfu.
Primer sequences are shown in Table 1.
Component Amt. per tube (μL) Final
Purified splinkerette adaptor ligated genomic DNA 5 -
Splink1 primer (0.1 μg/μL) 1 0.1 μg
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Component Amt. per tube (μL) Final
U3LTR#5 primer (0.1 μg/μL) 1 0.1 μg
dNTPs (25 mM) 0.5 0.25 mM
10× Pfu buffer 5 1×
Pfu Turbo Hotstart DNA polymerase (2.5 U/μL) 0.5 1.25 U
Double distilled Water 37 -
Final volume 50
15: The PCR protocol is as follows: 3 min at 94°C then 29 cycles of 15 sec at 94°C, 30 sec
at 68°C, 3 min at 72°C, with a final extension of 5 min at 72°C. A water only negative
control reaction should be run to test for possible reagent contamination.
Pause Point – The primary PCR reaction can be stored at −20°C indefinitely.
Secondary PCR Amplification – TIMING: 2 hr.
16: The secondary PCR primers are nested relative to the primers used in the primary PCR
and therefore increase the specificity of isolating virus/genome junctions. These primers
may also be barcoded and tagged with the 454 ‘primer A’ and ‘primer B’ sequences (Table
1). Set-up the secondary PCR as follows.
Component Amt. per tube (μL) Final
Primary PCR product 1 -
Splink2 primer (0.1 μg/μL)* 1 0.1 μg
U3LTR#1 primer (0.1 μg/μL)* 1 0.1 μg
Qiagen Multiplex Mastermix 25 -
Double distilled Water 22 -
Final volume 50
*Splink2-454 (A) and U3LTR#1-454 (B) must be used (see Table 1) if splinkerette PCR is to be sequenced on a 454
sequencer (see Step 19B).
17: The PCR protocol is as follows: 15 min at 94°C then 25 cycles of 15 sec at 94°C, 30 sec
at 60°C, 5 min at 72°C, with a final extension of 5 min at 72°C. A water only negative
control reaction should be run to test for possible reagent contamination.
Pause Point – The secondary PCR reaction can be stored at −20°C indefinitely.
Agarose Gel Analysis of splinkerette-PCR reactions – TIMING: 2 hr.
18: Visualize the results of the secondary splinkerette-PCR reaction by loading 15-20 μL on
a 2-4% agarose gel (in 1× TAE) with ethidium bromide (0.5 μg/mL). The PCR products
should appear as a ladder (Fig. 1c). The remaining PCR products should be purified using
the QIAquick Gel Extraction Kit (as described in step 12).
Caution – Ethidium bromide is a known mutagen and a suspected carcinogen.
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De-multiplexing and sequencing of splinkerette-PCR products
19: The splinkerette-PCR products now represent a pool that must be de-multiplexed prior to
sequencing. This can be done either by shotgun cloning and capillary read sequencing
(option A) or 454 sequence analysis (option B). 454 sequencing is only an option if the
secondary PCR has been performed using the Splink2-454 (A) primer and the
U3LTR#1-454 (B) primer (Table 1) since the ‘primer A’ and ‘primer B’ sequences in these
primers are essential for 454 sequencing.
A: Shotgun cloning prior to capillary read sequencing – TIMING: ~1 week.
i. To shotgun clone the PCR products set-up the following TOPO cloning reaction in
a 1.5 mL tube (note: Using the water supplied with the “TOPO TA Cloning® Kit”,
make a 1 in 4 dilution of the “salt solution” (1.2 M NaCl, 0.06 M MgCl2) before
using it in the cloning reaction listed below).
Component Amt. per tube (μL) Final
Purifed splinkerette DNA 1 -
pCR®4-TOPO® plasmid (10 ng/μL) 0.14 1.4 ng
Diluted (1/4) salt solution 1 0.05 M NaCl, 2.5 mM MgCl2
Double distilled water (supplied with kit) 3.9 -
Final volume 6.04
ii. Incubate the ligation at room temperature for 20 min before stopping the reaction
by transferring the tube to −80°C.
Pause Point – The Spinkerette PCR ligation reactions can be stored at −80°C indefinitely.
iii: To generate transformants of the ligation reactions, add 1 μL of the reaction and 50
μL of ElectroMax electrocompetent DH10B™ bacterial cells to a pre-chilled 0.1 cm
gap electroporation cuvette (sitting on ice). Transform the bacterial cells (electroporate
using the following conditions: 1.8 kV, 25 μF and 200 Ω).
iv: Recover transformants by addition of 1 mL SOC medium, transfer the transformants
to a 15 mL culture tube, and incubate in a shaking incubator at 37°C for 1 hr.
v: Plate transformants onto LB+amp plates (prepared as described in ‘reagent set up’)
and grow for 12-16 hr until colonies appear. Normally it is only necessary to plate 20
μL of the transformation to yield approximately 100-200 colonies per plate. Colony
numbers are usually reproducible because the ligation reaction is driven to completion.
Be sure to include a negative ‘no insert’ control to test reagents for contamination. The
remaining (unplated) transformation can stored at 4°C for up to 4 days or alternatively
glycerol stocks can be prepared by adding sterile glycerol to a final concentration of
15%.
vi: Pick colonies into deep-well 96-well plates containing 1 mL LB+amp medium
(prepared as described in ‘reagent set up’) per well and grow in a shaking incubator at
37°C for 12-16 hr. Purify plasmids from the colonies and sequence using standard
plasmid-based sequencing protocols17 on a high-throughput sequencing platform
described previously18.
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B: 454 ‘barcode’ sequencing of splinkerette-PCR reactions – TIMING: ~1 day.
i. An alternative approach of de-multiplexing and sequencing insertion sites is to use
454 parallel sequencing (Fig. 2)14.,For optimal results when using the 454 parallel
sequencing platform splinkerette-PCR products should be cleaned of any unwanted
dNTPs and primers – set up an Exo-Sap reaction usually in 96 well plates as
follows:
Component Amt. per tube (μL) Final
Splinkerette-PCR DNA 15 -
10× SAP buffer 2 20 mM Tris-HCl,10 mM MgCl2 (pH8)
Exonuclease I (20,000 U/mL) 0.25 5 U
Shrimp alkaline phosphatase (2,000 U/mL) 0.25 0.5 U
Double distilled water 2.50 -
Final volume 20
ii. Incubate the reaction at 37°C for 60 min, followed by 80°C for 20 min
iii. Purify the PCR products using a Millipore filter plate. Add 20 μl of PCR product
and 80 μL of HPLC water to the filter plate. Centrifuge the plate at 3,220 g for 10
min. Add 20 μL of HPLC water to the filter plate and centrifuge at 242 g for 10
min. Collect the re-suspended splinkerette-PCR products and place in a clean 96
well plate.
Pause point – The purified splinkerette-PCR can be stored at −80°C indefinitely.
iv: Quantify the splinkerette-PCR products on a nanodrop and then pool the samples.
We routinely pool 10-20 μL of PCR product from up to 100 splinkerette-PCR reactions
(the DNA can be concentrated by ethanol precipitation to reduce the total final volume
or using a Qiaquick column). The degree of multiplexing depends greatly on the
application and the expected complexity of the pool and it is probably best to optimize
this factor for each experiment. We have designed primers so that in the second
splinkerette-PCR primer B is incorporated into the splinkerette product at the LTR end
and primer A is incorporated at the linker end.
v: Emulsion PCR should then be performed on these products using “GS emPCR kit
III” from Roche. A short nucleotide ‘barcode’ in the LTR end primer is used as a tag to
computationally de-multiplex the 454 splinkerette-PCR sequences. A list of suitable
barcodes, designed to lack homopolymer stretches, is provided in Supplementary Table
1.
CRITICAL STEP The choice of barcodes should be carefully considered depending on the
application. 5 bp barcodes represent a minimum length that should be used. 10 bp is optimal.
To increase the unambiguous assignment of sequences to tumours within the pool of
sequenced products it may be desirable to use longer barcode sequences. Barcode length
largely depends of the degree of multiplexing within each pool19.
DNA sequence trace analysis
20: After the DNA sequences have been generated they need to be analyzed. The first phase
of this process is to remove contaminating sequence by identifying and discarding those
sequence traces that do not contain the end of the LTR and where the barcode cannot be read
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if sequencing was performed on the 454 platform. Software for mapping and analysis of
insertion sites within the remaining sequences has been described elsewhere13,20-23.
Timing
The entire splinkerette-PCR procedure usually takes 4-5 days depending on the duration of
the digestion and ligation steps.
Step 2: Extraction of tumour genomic DNA: 4 hr
Steps 3-4: Digestion of tumour genomic DNA with Sau3AI: 12-16 hr
Steps 5-8: Splinkerette adaptor ligation: 12 hr
Steps 9-11: Digestion to remove genomic DNA fragments with splinkerette-adaptor ligated
on both ends: 6 hr
Step 12: Clean-up of EcoRV digestion reaction: 10 min
Steps 14-15: Primary PCR amplification: 2 hr
Steps 16-17: Secondary PCR amplification: 2 hr
Step 18: Agarose gel analysis: 2hr
Step 19A: Shotgun cloning prior to capillary read sequencing ~1 week
Step 19B: 454 ‘barcode sequencing of splinkerette-PCR reactions ~1 day
Step 20: DNA sequence trace analysis ~ 1 week
Troubleshooting
Troubleshooting advice can be found in Table 2.
Anticipated Results
We have successfully used this approach to generate the DNA sequence of over 1,000
splinkerette-PCR reactions generated using both viruses and transposons. Successful
splinkerette-PCR will yield a ladder of bands (Fig. 1c). The number and the size of the
bands greatly depends on the number of insertion sites in the tumour. When analysing large
numbers of tumours it is important to perform several splinkerette-PCR reactions on control
genomic DNA that does not contain any viral or transposon insertions. This is because there
are elements such as pseudo-LTR or pseudo-transposon repeat-like sequences in every
genome and these may be non-specifically amplified. Although rare, mispriming of
splinkerette primers can also yield PCR artefacts. Sequencing of a splinkerette-PCR product
is the only sure way to ensure that it faithfully represents a true insertion site.
Supplementary Table 1: 10 bp sequences suitable for ‘barcoding’ splinkerette products for
454 sequencing. These sequences facilitate the computational ‘demultiplexing’ of pooled
splinkerette-PCR products following 454 sequencing.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Overview of the splinkerette-PCR protocol. A. The steps performed to generate splinkerette-
PCR products for sequencing. E and S refer to EcoRV and Sau3AI, respectively. B. The
structure of the splinkerette-adaptor. C. The expected result for a successful splinkerette-
PCR reaction. The first lane of this 4% gel is a 100 bp marker followed by duplicate
splinkerette-PCR reactions for 6 MuLV tumour samples.
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Figure 2.
There are two methods for high-throughput sequencing of splinkerette-PCR products. These
include the ‘TOPO-shotgun’ approach where pools of splinkerette-PCR products from each
tumour are individually shotgun cloned and sequenced on a capillary sequencing platform,
and the 454 sequencing approach where spinkerette-PCR products from multiple tumours
are pooled together and subjected to single molecule sequencing on the 454 platform. When
454 sequencing is used, products from individual splinkerette-PCR reactions are barcoded
(BC) using a short nucleotide ‘tag’ sequence and the second round PCR primers contain
sequences for primer A and primer B which are necessary for the emulsion PCR and
sequencing steps on the 454 platform.
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Table 1
Oligonucleotides required for this protocol
The underlined sequences are the 454 Primer A (normal text) and 454 Primer B (Italics) sequences
respectively. The bold XXXXXXXXXX represents the 10bp barcode sequence used to identify each tumour.
A list of suitable barcodes is provided in the supplementary Table 1.
Name Sequence (5′ to 3′) Comment
For standard splinkerette-PCR:
Long strand adapter CGAAGAGTAACCGTTGCTAGGAGAGACCGTGGCTGAATGAGACTGGTGTCGACACTAGTGG Add bases to 3′ end
for
3′ overhang enzymes
Short strand adapter GATCCCACTAGTGTCGACACCAGTCTCTAATTTTTTTTTTCAAAAAAA Contains hairpin and
GATC 5′ overhang
Splink1 CGAAGAGTAACCGTTGCTAGGAGAGACC 1st round PCR primer
on splinkerette
adaptor
U3 LTR#5 GCGTTACTTAAGCTAGCTTGCCAAACCTAC 1st round PCR primer
on MuLV viral LTR
Splink2 GTGGCTGAATGAGACTGGTGTCGAC 2nd round PCR primer
on splinkerette
adaptor
U3 LTR#1 CCAAACCTACAGGTGGGGTCTTTC 2nd round PCR primer
on MuLV viral LTR
For 454 splinkerette-PCR:
Splink2-454A GCCTCCCTCGCGCCATCAGGTGGCTGAATGAGACTGGTGTCGAC 2nd round PCR primer
adapted with 454
primer A
U3 LTR#1-454B GCCTTGCCAGCCCGCTCAGXXXXXXXXXX CCAAACCTACAGGTGGGGTCTTTC 2nd round PCR primer
adapted with 454
primer B
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Table 2
Troubleshooting
Step Problem Solution
18 No splinkerette-PCR products on gel The splinkerette-PCR reaction has many steps and as such are there are numerous places
where the protocol may fail. The most frequent source of failure is an incorrect ratio of
splinkerette-adaptor to genomic DNA in the splinkerette ligation. Be sure to carefully
prepare the splinkerette-adaptor and to quantify the genomic DNA prior to digestion.
20 Chimeric splinkerette products One of the major contaminants in splinkerette-PCR is chimeric genomic sequences ligated
between the LTR and the adaptor. These are splinkerettes carrying multiple genomic
fragments between the end of the insertional mutagen and the linker. It is very hard to
remove these by modifying the splinkerette-PCR reaction but these should be carefully
masked out when the sequence data is analyzed.
20 Linker – genomic DNA – linker products Occasionally linker – genomic DNA – linker fragments are generated.
The generation of these products is suppressed by cutting with an internal enzyme or they
can be masked out during the analysis of the sequence.
Nat Protoc. Author manuscript; available in PMC 2013 April 16.
